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http://www.biomedcentral.com/1471-2407/14/676RESEARCH ARTICLE Open AccessImmunohistochemical detection improves the
prognostic value of lymphatic and blood vessel
invasion in primary ductal breast cancer
Fadia J A Gujam1,4*, James J Going2, Zahra M A Mohammed3, Clare Orange2, Joanne Edwards4
and Donald C McMillan1Abstract
Background: Lymphovascular invasion (LBVI) including lymphatic (LVI) and blood (BVI) vessel invasion is a critical
step in cancer metastasis. In breast cancer, the optimal detection method of LBVI remains unclear. This research aimed
to compare the prognostic value of different assessments of the LVI and BVI in patients with early breast cancer.
Methods: The study cohort included 360 patients with a median follow-up of 168 months. LBVI on H&E sections
(LBVIH&E) was reviewed centrally and blinded to the pathology report. Immunohistochemical staining for D2-40 and
Factor VIII was performed to identify LVID2–40 and BVIFVIII.
Results: LBVIH&E, LVID2–40 and BVIFVIII were present in 102 (28%), 127 (35%) and 59 (16%) patients respectively.
In node-negative patients (206), LBVIH&E, LVID2–40 and BVIFVIII were present in 41 (20%), 53 (26%) and 21 (10%)
respectively. In triple-negative patients (120), LBVIH&E, LVID2–40 and BVIFVIII were present in 35 (29%), 46 (38%)
and 16 (13%) respectively. LBVIH&E was significantly associated with tumour recurrence in the whole cohort
(P < 0.001), node-negative patients (P = 0.001) and triple-negative patients (P = 0.004). LVID2–40 and BVIFVIII were
significantly associated with tumour recurrence in whole cohort, node-negative (all P < 0.001) and triple-negative
patients (P = 0.002). In multivariate survival analysis, only LVID2–40 and BVIFVIII were independent predictors of cancer
specific survival in the whole cohort (P = 0.023 and P < 0.001 respectively), node-negative patients (P = 0.004 and P = 0.001
respectively) and triple-negative patients (P = 0.014 and P = 0.001 respectively).
Conclusion: Assessment of LVI and BVI by IHC using D2-40 and Factor VIII improves prediction of outcome in patients
with node-negative and triple-negative breast cancer.Background
Breast cancer is a common cancer in female and one of
the leading causes of cancer death in women. It accounts
for approximately one tenth of all new cancers and a quarter
of all female cancer cases [1]. In the UK more than 49,000
women diagnosed with breast cancer in 2011 accounting for
30% of female cancer incidence. However, the survival rate
has improved with 78% surviving 10 or more years [2].
Lymphovascular invasion (LBVI) including lymphatic
(LVI) and blood (BVI) vessel invasion is a critical step in* Correspondence: f.gujam.1@research.gla.ac.uk
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unless otherwise stated.cancer metastasis. It refers to the invasion of tumour
cells into endothelium-lined lymphatic and/or blood vessels
[3,4]. In breast cancer LBVI has been recognised more than
four decades ago [5]. Since then, a number of independent
studies have investigated the prognostic value of LBVI in
node-negative and node-positive breast cancer [6-17].
The College of American Pathologists (CAP) consensus
(1999) and 11th St Gallen meeting (2009) did not agree
on the need for specific stains to identify vascular spaces
or to distinguish specifically between LVI and BVI [18,19].
Although staging guidelines of the American Joint Cancer
Committee on Cancer (2005) mandates distinguishing
between lymphatic and blood vessel invasion, these guide-
lines lack a routine standardised and objective assessment
method to reliably differentiate them [20]. It remains a
challenge to distinguish true LVI and BVI from retractionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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on haematoxylin and eosin (H&E) stained sections [21-23].
Numerous studies have reported that LBVI and LVI
are powerful prognostic factors of poorer survival in
patients with early breast cancer using both H&E and
IHC approaches [24]. While immunohistochemistry (IHC)
appears more reliably to detect LBVI and LVI than H&E,
the prognostic role of BVI and optimal detection methods
remain unclear [24].
The aim of the present study was to examine the prog-
nostic value of different assessments of LVI and BVI in
patients with early, and in particular node-negative and
triple-negative breast cancers.
Methods
Patients
Patients with invasive ductal breast cancer, who had
undergone surgery between the years 1995 to 1998 at
Royal Infirmary, Western Infirmary, Victoria or Stobhill
Hospitals, Glasgow, and had formalin-fixed paraffin-
embedded blocks of the primary tumour available for
evaluation were studied (n = 360). Clinicopathological data
including age, histological tumour type, grade, tumour size,
lymph node status, adjuvant treatment (hormonal therapy
and chemotherapy) were retrieved from the routine reports.
ER and PR status, using tissue microarrays, were assessed
according to the American Society of Clinical Oncology
and College of American Pathologists guidelines with cut-
off value of 1% positive tumour nuclei [25]. HER2 status
were assessed visually using tissue microarrays as previously
described i.e. a score 3+ is regarded as positive; 2+ is
regarded as equivocal, leading to referral for HER2 FISH;
and 0 and 1+ are regarded as negative [26].
The patients included in this study did not receive
neoadjuvant therapy or adjuvant anti-HER-2 therapy.
The inclusion of ductal breast cancers only was to limit
the potential confounding effects of other tumour types
on the analysis in the present study.
Patients were routinely followed up following surgery.
Date and cause of death was crosschecked with the cancer
registration system and the Registrar General (Scotland).
Death records were complete until 31st of May 2013 and
that served as the censor date. Cancer recurrence was
measured from the date of primary surgery until the date
of first recurrence of breast cancer. Cancer specific sur-
vival was measured from the date of primary surgery until
the date of death from breast cancer.
The Research Ethics Committee of North Glasgow
University Hospitals approved the use of human tissue
in this study.
Immunohistochemistry
For visualization of lymphatic and blood vessels, 2 con-
secutive samples of 2.5 μm thick sections from eachblock (one block/case) were stained for the lymph-
atic endothelial marker D2-40 (Covance, Monoclonal
Antibody, SIG-3730, USA) diluted 1:100 and Factor
VIII (Mouse Monoclonal Antibody, NCL-L-Vwf, Leica,
Newcastle, UK) diluted 1:100. Sections were dewaxed
in xylene and rehydrated through descending concen-
trations of ethanol. For antigen retrieval of Factor VIII,
sections were microwaved for 14 minutes in sodium
citrate buffer (pH 6). Endogenous hydrogen peroxidase
activity was blocked with 3% H2O2 for 15 minutes.
Non-specific binding was blocked by incubation with 10%
horse serum for 30 minutes. Sections were subsequently
incubated with the respective primary antibody; 60 minutes
at room temperature for D2-40 and 30 minutes at 25°C
for Factor VIII. Sites of binding were detected using
the Envision technique (Dako, code K5007) with 3–30
diaminobenzidine (Vector, code SK 4001, Burlingame,
CA, USA), as chromogenic substrate, according to the
manufacturer’s instruction. Slides were counterstained
with haematoxylin were dehydrated and mounted with
DPX. Two full sections of tonsil tissue were used as
positive and negative controls for each antibody.
Slide scanning and scoring
Stained sections with H&E, D2-40 and Factor VIII were
scanned at objective magnification × 20 by Hamamatsu
NanoZoomer (Hertfordshire, UK). Assessment of LBVIH&E,
LVID2-40 and BVIFactorVIII were carried out on a computer
monitor using the Slidepath Tissue IA system version 3.0
(Slidepath, Leica Biosystems).
Assessment of LBVI, LVI and BVI
LBVI on H&E sections (LBVIH&E) was reviewed cen-
trally and blinded to the pathology report. For the as-
sessment of LVID2–40 and BVIFVIII serial sections,
similar to that of H&E sections, from each block were
stained with D2-40 and Factor VIII. LBVIH&E, LVID2–40
and BVIFVIII were identified at peritumoural, invasive
front or intratumoural areas. LBVIH&E was identified
using criteria previously described [6], as the presence
of tumour cell emboli within a vessel space, which
were identified by associated fibrin clot and/or an
endothelial cell lining. LVID2–40 was identified by
tumour cells within D2-40-positively stained vessels,
while BVIFVIII was counted only when tumour cells
were identified in D2-40-negative, Factor VIII-positive
vessels. A total of 30% of H&E and IHC stained sections
for LBVI, LVI and BVI were independently scored by
two observers (FJAG, ZMAM) blinded to patient out-
come and the other observer’s score. The inter class
correlation coefficient (ICCC) of ≥0.84 was obtained
for H&E, D2-40 and Factor VIII indicated excellent
agreement, and FG scored all the slides and this data
was used in the analysis.
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Consistency between the observers was analysed using the
ICCC. Interrelationships between variables were assessed
using contingency table analysis with X2 test for trend as
appropriate. Univariate and multivariate survival ana-
lysis were performed using the Kaplan-Meier analysis
and Cox proportional hazards model with a stepwise
backward elimination to derive a final model of vari-
ables with a significant independent relationship with
survival. All statistical analyses were 2-sided with sig-
nificance defined as a P value <0.05. Deaths up to May
2013 were included in the analysis. All statistical ana-
lysis was performed using the SPSS software version 19
(SPSS Inc., Chicago, IL, USA).
Results
Clinico-pathological characteristics and LBVIH&E, LVID2-40
and BVIFVIII in the whole cohort, in node-negative patients
and in triple-negative patients
The clinical and pathological characteristics of the 360
patients are shown in Table 1. Majority of patients were
older than 50 years (65%), had tumours size less than
2 cm (51%), had grade III carcinoma (52%) and no axillary
lymph node involvement (57%). A total of 189 patients
(53%) had ER positive tumours and 166 patients (46%)
had PR positive tumours. Two hundred eighty nine patients
(80%) had HER2 negative tumours with 33% of patients
had triple-negative tumours. 81 patients received endocrine
based treatment (22%) and 144 received chemotherapy
(40%). No information on chemotherapy was available on
7 patients (2%). Eighty nine patients (24%) experienced re-
currences. Of these patients, 17 (5%) had local recurrence,
67 (19%) had distant recurrence and 5 patients had both.
LBVIH&E was readily identified when tumour cells
invaded into large vessels and especially when lymphaticTable 1 The clinico-pathological characteristics of patients
with primary operable invasive ductal breast cancer
(n = 360)
Clinico-pathological characteristics Patients, n (%)
Age (≤50/ >50 years) 125(35%)/235(65%)
Size (≤20/ 21-50/ >50 mm) 185(51%)/162(45%)/13(4%)
Grade (I / II / III) 48(13%)/124(34%)/188(52%)
Involved lymph node (−ve/+ve) 206(57%)/154(43%)
ER status (no/yes) 171(47%)/189(53%)
PR status (no/yes) 194(54%)/166(46%)
HER2 status (no/yes) 289(80%)/71(20%)
Triple-negative tumours (no/yes) 240(67%)/120(33%)
Endocrine therapy (no/yes/unknown) 272(76%)/81(22%)/7(2%)
Chemotherapy (no/yes/unknown) 209(58%)/144(40%)/7(2)
Tumour recurrence (no/local/distant/both) 271(75%)/17(5%)/67(19%)/5(1%)
Alive/cancer death/non cancer death 189(53%)/97(27%)/74(21%)vessels were accompanied by adjacent blood vessels,
however, invasion into small lymphatic or blood vessels
as well as stromal artifact could be difficult to assess
(Figure 1). D2-40 stained vessels were usually clear and
readily assessed. LVID2–40 was identified by the presence of
tumour emboli in vessels that showed D2-40 positivity
of the endothelium. Although D2-40 was positive in
myoepithelial cells of breast ducts in some cases, this
was readily distinguished from lymphatic endothelium
by morphological characteristics (Figure 1L).
D2-40 staining was helpful in identifying small lymphatic
emboli and lymphatic vessels obscured by tumour cells
(Figure 1). Blood vessels were intensely and continuously
positive for Factor VIII. Factor VIII staining of lymphatic
endothelium was faint or negative (Figure 1). LVID2–40
was generally more extensive than BVIFVIII and lymphatic
tumour emboli were larger than blood vessel emboli.
LBVIH&E was reported in 102/360 (28%) patients,
LVID2-40 was present in 127/360 (35%) patients and BVIFVIII
was present in 59/360 (16%) patients. Eighty nine (25%) pa-
tients had LVI only, whereas twenty one (6%) patients had
BVI only, and thirty eight (10%) had both LVI and BVI.
LBVIIHC (LVID2-40 + BVIFVIII) was present in148 (41%)
patients. In node-negative patients (206), LBVIH&E was
present in 41 (20%), LVID2-40 was present in 53 (26%) and
BVIFVIII was present in 21 (10%). In triple-negative patients
(120), LBVIH&E was present in 35 (29%), LVID2-40 was
present in 46 (38%) and BVIFVIII was present in 16(13%).
While LBVIH&E was strongly associated with LBVIIHC
(P < 0.001), 80 (22%) patients in whom LBVIH&E had not
been identified were positive for LVID2-40 and/or BVIFVIII.
Also, in 34 patients (9%) in whom LBVIH&E had been iden-
tified, IHC was negative for both LVID2-40 and BVIFVIII.
As shown in Table 2, the presence of LBVIH&E was
associated with large tumour size (P < 0.001), high tumour
grade (P = 0.028), involved lymph node (P < 0.001), and
tumour recurrence (P < 0.001). No association was seen
with hormonal status, HER2 status and endocrine therapy
however, there was a trend toward increased chemotherapy
(0.067). In node-negative patients, only tumour size
(P = 0.008) and tumour recurrence (P = 0.001) were sig-
nificantly associated with LBVIH&E. In triple-negative
patients, the presence of LBVIH&E was associated with
tumour size (P = 0.025), involved lymph node (P =0.009),
and tumour recurrence (P = 0.004).
Table 3 shows that the presence of LVID2-40 was asso-
ciated with younger age (P = 0.006), large tumour size
(P = 0.038), high tumour grade (P < 0.001), involved lymph
node (P < 0.001), reduced endocrine therapy (P = 0.014),
increased chemotherapy (P = 0.002) and tumour recurrence
(P < 0.001). In node-negative patients, the presence of
LVID2-40 was associated with younger age (P = 0.008) large
tumour size (P = 0.019) and high tumour grade (P = 0.002),
HER2 negativity (P = 0.032) and tumour recurrence
Figure 1 Examples of LVI and BVI in invasive breast cancer sections stained with H&E, D2-40 and Factor VIII. A: H&E conspicuous
carcinoma emboli in large and small vascular spaces (single arrows) accompanying structurally identified blood vessels (double arrows). B: similar
section stained with D2-40 confirming that these are LVI (arrows). C: carcinoma emboli in small vessels (arrows) that could not be characterised
on H&E section. D: similar section stained with D2-40 confirming that these are LVI (arrows). (Scale bar 100 μm). E & G: carcinoma cells within
Factor VIII-positive vessels. These are negative for D2-40 (F & H), indicating BVI. (Scale bar 10 μm). I-K show consecutive sections stained with
H&E (I) showing tumour cells inside endothelial lining space, however, D2-40 (J) and Factor VIII (K) are both negative suggesting stromal artifact
(note positive staining of blood vessel with Factor VIII). L: pattern of D2-40 staining in normal breast duct myoepithelium (single arrows) and how
it is different from that of lymphatic endothelium (double arrows). (Scale bar100 μm).
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endocrine therapy (P = 0.070), and increased chemotherapy
(P = 0.070). In triple-negative patients, the presence
of LVID2-40 was associated with involved lymph node
(P = 0.001) and tumour recurrence (P < 0.001).
Table 4 shows that the presence of BVIFVIII was associated
with large tumour size (P < 0.001), high tumour grade
(P = 0.044), involved lymph node (P < 0.001), HER2 nega-
tivity (P = 0.003) and tumour recurrence (P < 0.001). There
was no association with hormonal status or treatment re-
ceived. In node-negative patients, BVIFVIII was only signifi-
cantly associated with larger tumour size (P = 0.002) and
tumour recurrence (P < 0.001). In triple-negative patients,
the presence of BVIFVIII was significantly associated with
tumour size (P = 0.037), involved lymph node (P = 0.019)
and tumour recurrence (P = 0.002).
Survival analysis of LBVIH&E, LVID2-40 and BVIFVIII in the
whole cohort, in node-negative patients and in
triple-negative patients
The minimum follow-up of survivors was 142 months;
median follow-up of survivors was 168 months. During
follow up 171 patients died, 97 died of their cancer. The
presence of LBVIH&E, LVID2-40 and BVIFVIII were analysedwith 15 years follow-up data using the Kaplan–Meier
analysis and Cox regression.
Kaplan–Meier curves showed increased risk of death
with LBVIH&E, LVID2-40 and BVIFVIII in the whole cohort,
node-negative and triple-negative patients (Figure 2).
Univariate analysis indicated that LBVIH&E was signifi-
cantly associated with cancer specific survival in the
whole cohort (P < 0.001), node-negative (P = 0.010) and
in triple-negative patients (P = 0.011). The Presence of
LVID2-40 was strongly and significantly associated with
cancer specific survival in the whole cohort (P < 0.001), in
node-negative patients (P = 0.001) and in triple-negative
patients (P < 0.001). The presence of BVIFVIII was strongly
and significantly associated with cancer specific survival
in the whole cohort, node-negative and triple-negative
patients (all P < 0.001) (Table 5).
In multivariate survival analysis, tumour size (P = 0.014),
LN status (P = 0.008), LVID2-40 (P = 0.023) and BVIFVIII
(P < 0.001) remained independently associated with cancer
specific survival. In multivariate survival analysis for
node-negative patients, tumour size (P = 0.034), LVID2-40
(P = 0.004) and BVIFVIII (P = 0.001) remained independent
predictors of shorter cancer specific survival. In multivariate
survival analysis for triple-negative patients, tumour size
Table 2 The inter-relationship between clinico-pathological
characteristics and lymphovascular invasion (LBVIH&E) in
patients with primary operable invasive ductal breast cancer
All patients (n = 360) LBVIH&E -ve LBVIH&E + ve (P-value)
n = 258(72%) n = 102(28%)
Age (≤50/ >50 years) 86/175 39/63 0.379
Size (≤20/ 21-50/ >50 mm) 147/106/5 38/56/8 <0.001
Grade (I / II / III) 38/95/125 10/29/63 0.028
Involved lymph node (−ve/+ve) 165/93 41/61 <0.001
ER status (no/yes) 119/139 52/50 0.406
PR status (no/yes) 137/121 57/45 0.634
HER2 status (no/yes) 211/47 78/24 0.254
Tumour recurrence
(no/local/distant/both)
213/7/36/2 58/10/31/3 <0.001
Endocrine therapy (no/yes) 191/63 81/18 0.184
Chemotherapy (no/yes) 158/96 51/48 0.067
Alive/cancer death/non
cancer death
148/54/56 41/43/18 0.158
Cancer specific
survival (months)a
178(171–188) 138(121–155) <0.001
Node-negative
patients (n = 206)
n = 165(80%) n = 41(20%)
Age (≤50/ >50 years) 51/114 16/25 0.322
Size (≤20/ 21-50/ >50 mm) 103/60/2 17/22/2 0.008
Grade (I / II / III) 29/60/76 5/13/23 0.233
ER status (no/yes) 40/53 32/29 0.252
PR status (no/yes) 47/46 34/27 0.529
HER2 status (no/yes) 138/27 30/11 0.123
Endocrine therapy (no/yes) 118/46 31/9 0.479
Chemotherapy (no/yes) 113/51 29/11 0.658
Tumour recurrence
(no/local/distant/both)
143/6/15/1 27/2/10/2 0.001
Alive/cancer death/non
cancer death
104/23/38 20/12/79 0.365
Cancer specific
survival (months)a
190(181–199) 168(146–190) 0.010
Triple-negative
patients (n = 120)
n = 85(71%) n = 35(29%)
Age (≤50/ >50 years) 31/54 19/16 0.073
Size (≤20/ 21-50/ >50 mm) 49/34/2 14/17/6 0.025
Grade (I / II / III) 1/14/70 0/7/28 0.888
Involved lymph node (−ve/+ve) 56/29 14/21 0.009
Tumour recurrence
(no/local/distant)
69/1/15 19/2/14 0.004
Endocrine therapy (no/yes) 76/8 31/4 0.754
Chemotherapy (no/yes) 36/48 15/20 0.999
Alive/cancer death/non
cancer death
50/20/15 16/17/2 0.936
Cancer specific
survival (months)a
171(155–187) 123(96–150) 0.011
a = Mean (95% CI).
Table 3 The inter-relationship between clinico-pathological
characteristics and lymphatic invasion (LVID2-40) in patients
with primary operable invasive ductal breast cancer
All patients (n = 360) LVID2–40-ve LVID2–40+ve (P-value)
n = 233
(65%)
n = 127
(35%)
Age (≤50/ >50 years) 69/164 56/71 0.006
Size (≤20/ 21-50/ >50 mm) 129/97/7 56/65/6 0.038
Grade (I / II / III) 156/73/13 56/53/21 <0.001
Involved lymph node (0/1-3/ >3) 153/80 53/74 <0.001
ER status (no/yes) 102/131 69/58 0.056
PR status (no/yes) 118/115 76/51 0.095
HER2 status (no/yes) 193/40 96/31 0.099
Endocrine therapy (no/yes) 168/62 104/19 0.014
Chemotherapy (no/yes) 150/80 59/64 0.002
Tumour recurrence
(no/local/distant/both)
199/5/28/1 72/12/39/4 <0.001
Alive/cancer death/non
cancer death
141/39/53 48/58/21 0.059
Cancer specific survival (months)a 186(177–194) 134(120–149) <0.001
Node-negative disease (n=206) n=153 (74%) n=53 (26%)
Age (≤50/ >50 years) 42/111 25/28 0.008
Size (≤20/ 21-50/ >50 mm) 96/55/2 24/27/2 0.019
Grade (I / II / III) 33/53/67 1/20/32 0.002
ER status (no/yes) 32/48 40/34 0.082
PR status (no/yes) 38/42 43/31 0.189
HER2 status (no/yes) 130/23 38/15 0.032
Endocrine therapy (no/yes) 106/46 43/9 0.070
Chemotherapy (no/yes) 111/41 31/21 0.070
Tumour recurrence
(no/local/distant/both)
137/4/11/1 33/4/14/2 <0.001
Alive/cancer death/non
cancer death
99/18/36 25/17/11 0.266
Cancer specific survival (months)a 198(190–206) 153(131–174) 0.001
Triple-negative patients (n=120) n=74(62%) 46(38%)
Age (≤50/ >50 years) 26/48 24/22 0.064
Size (≤20/ 21-50/ >50 mm) 42/28/4 21/23/2 0.367
Grade (I / II / III) 1/13/60 0/8/38 0.712
Involved lymph node (−ve/+ve) 52/22 18/28 0.001
Endocrine therapy (no/yes) 65/9 42/3 0.336
Chemotherapy (no/yes) 36/38 15/30 0.103
Tumour recurrence
(no/local/distant)
64/0/10 24/3/19 <0.001
Alive/cancer death/non
cancer death
48/13/13 18/24/4 0.217
Cancer specific survival (months)a 176(161–192) 122(96–147) <0.001
a = Mean (95% CI).
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Table 4 The inter-relationship between clinico-pathological
characteristics and blood vessel invasion (BVIFVIII) in patients
with primary operable invasive ductal breast cancer
All patients (n = 360) BVIFVIII -ve BVIFVIII + ve (P-value)
n = 301
(84%)
n = 59
(16%)
Age (≤50/ >50 years) 104/197 21/38 0.848
Size (≤20/ 21-50/ >50 mm) 168/123/10 17/39/3 <0.001
Grade (I / II / III) 45/104/152 3/20/36 0.044
Involved lymph node (−ve/+ve) 185/116 21/38 <0.001
ER status (no/yes) 139/162 32/27 0.258
PR status (no/yes) 158/143 36/23 0.230
HER2 status (no/yes) 250/51 39/20 0.003
Endocrine therapy (no/yes) 226/70 46/11 0.475
Chemotherapy (no/yes) 178/118 31/26 0.419
Tumour recurrence
(no/local/distant/both)
243/13/42/3 28/4/25/2 <0.001
Alive/cancer death/non
cancer death
179/60/62 10/37/12 <0.001
Cancer specific survival (months)a 181(173–189) 93(73–112) <0.001
Node-negative disease (n=212) n=185 (90%) n=21 (10%)
Age (≤50/ >50 years) 58/132 10/12 0.157
Size (≤20/ 21-50/ >50 mm) 118/69/3 6/15/1 0.002
Grade (I / II / III) 36/66/88 1/9/12 0.180
ER status (no/yes) 50/66 22/16 0.114
PR status (no/yes) 58/58 23/15 0.261
HER2 status (no/yes) 158/32 16/6 0.228
Endocrine therapy (no/yes) 133/50 16/5 0.732
Chemotherapy (no/yes) 129/54 13/8 0.419
Tumour recurrence
(no/local/distant/both)
163/9/15/3 12/0/10/0 <0.001
Alive/cancer death/non
cancer death
125/24/41 3/11/8 0.001
Cancer specific survival (months)a 194(186–202) 110(75–146) <0.001
Triple-negative patients (n=120) n=104(87%) n=16(13%)
Age (≤50/ >50 years) 44/60 6/10 0.718
Size (≤20/ 21-50/ >50 mm) 59/40/5 4/11/1 0.037
Grade (I / II / III) 1/16/87 0/5/11 0.212
Involved lymph node (−ve/+ve) 65/39 5/11 0.019
Endocrine therapy (no/yes) 92/12 15/0 0.167
Chemotherapy (no/yes) 45/59 6/9 0.812
Tumour recurrence
(no/local/distant)
81/3/20 7/0/9 0.002
Alive/cancer death/non
cancer death
64/24/16 2/13/1 0.014
Cancer specific survival (months)a 172(157–186) 64(37–92) <0.001
a = Mean (95% CI).
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BVIFVIII (P = 0.001) remained independently associated with
cancer specific survival (Table 5).
Discussion
The results of the present study show that LBVIH&E,
LVID2-40 and BVIFVIII all predicted tumour recurrence
and cancer specific survival in an observational cohort
of patients with early breast cancer. These results make
a case for routine clinical assessment of lymphatic and
blood vessel invasion by IHC to ascertain LVI and BVI.
In the present study, the proportion of patients with
LBVIH&E (28%) was consistent with most previous studies
of breast cancer compared with (22-48%) in the literature,
(20%) compared with (15-28%) for patients with node-
negative tumour, and (29%) compared with (24-45%) for
patients with triple-negative tumour [24]. Similarly, in
terms of the association between LBVIH&E and other well
established high risk features such as tumour size, LN
status, tumour grade, and breast cancer recurrence and
survival are consistent with previous studies. Therefore, the
present cohort is consistent with previous reports in which
the prognostic value of LBVIH&E has been established.
In the present study, the proportion of patients with
LVID2-40 (35%) was consistent with most previous studies
using a similar approach (28-46%), (26%) compared with
(15-28%) for patients with node-negative tumour, and
(38%) compared with (26-41%) for patients with triple-
negative tumour [24]. LVID2-40 was associated with other
well established high risk features such as tumour size,
LN status, tumour grade, and with tumour recurrence.
In addition, the presence of LVID2-40 was significantly
associated with reduced hormonal treatment and in-
creased chemotherapy.
Furthermore, the presence of LVID2-40 provided inde-
pendent prognostic information not only in the whole
cohort but also in the subgroup of patients with lymph
node-negative and triple-negative breast cancer. These
results are consistent with recent studies that assessed
LVI objectively using D2-40 [16,17,27,28]. Thus, the present
study confirms that D2-40 staining is a practical and ef-
fective way of identifying endothelial cells lining lymphatic
vessels in patients with early breast cancer, in particular
node-negative disease. These findings suggest that LVID2-40
might usefully be incorporated into the routine clinical
pathological staging of patients with breast cancer.
In the present study, the proportion of patients with
BVI (Factor VIII) was lower than that of previous studies
by Kato and colleagues that used a similar approach (16%)
compared to (27-29%) in the whole cohort and (10%) com-
pared to (18%) in node-negative patients [15,29,30]. Given
that Kato and colleagues did not use a specific lymphatic
marker such as D2-40 to differentiate between lymphatic
and blood vessels and that Factor VIII has been found to be
Figure 2 Comparison of Kaplan-Meier survival curves (Log rank) of cancer specific survival for LBVIH&E, LVID2-40 and BVIFVIII in whole
cohort (A-C), node-negative patients (D-F) and triple-negative patients (G-I).
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that the higher rate reported by Kato and co-workers
reflects LVI being assessed as BVI. Moreover, the present
cohort would not explain the large discrepancy between
the present BVI rate and that reported by Mohammed and
colleagues [16,17] of only 0.7% of cases. Clearly, further
prospective work is required across multiple centres to
standardise the reporting of BVI, an important determinant
of outcome in primary operable ductal breast cancer.
The results of the present study show for the first time
the significance of BVI in triple-negative breast cancer.
This is an important finding, because currently used
clinic-opathologic and molecular markers, including
the recent multigene assays, have a limited prognostic
value in this molecular subtype. Most of these tumours
are of high grade and exhibit poor prognosis gene sig-
natures [31-33]. Thus objective assessment of BVI may
provide additional independent prognostic information
for this clinically important subgroup, in whom risk
stratification and decisions about systemic therapy need to
be determined.The results of the present study suggest that BVI is
less frequent than LVI in breast cancer, consistent with
previous studies [15,22,34,35]. This would suggest that
LVI is potentially a more important route of breast cancer
spread. However, results of the present study show that
twenty one of 212 patients (10%) without lymph node me-
tastases had BVI. Blood vessel invasion in patients without
lymph node metastases may explain the subsequent devel-
opment of metastatic disease.
It is recognised that D2-40 may stain myoepithelial
cells of the normal breast ducts and ductal carcinoma in
situ (DCIS) especially in small ducts completely filled by
solid-pattern DCIS [36-38]. There is evidence that p63
staining may be useful in distinguishing D2-40 positive
myoepithelium. However, this would increase the complex-
ity of the present approach for routine clinical pathological
analysis. Moreover, with awareness that myoepithelium
may also be immunoreactive largely obviates this problem.
Specifically, the tumour growth pattern enables distinction
of ductal carcinoma in situ from lymphovascular invasion.
Also, the myoepithelium is discontinuous in small ducts
Table 5 The relationship between clinic-pathological characteristics and cancer specific survival in patients with primary
operable invasive ductal breast cancer
All patients (n = 360) Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (≤50/ >50 years) 0.97(0.64-1.45) 0.861
Size (≤20/ 21-50/ >50 mm) 2.16(1.52-3.05) <0.001 1.58(1.09-2.29) 0.014
Grade (I / II / III) 1.84(1.31-2.57) <0.001 1.43(1.00-2.05) 0.049
Involved lymph node (−ve/+ve) 2.83(1.87-4.28) <0.001 1.82(1.17-2.83) 0.008
ER (no/yes) 0.59(0.39-0.89) 0.012 0.571
PR (no/yes) 0.72(0.48-1.09) 0.128
HER2 status (no/yes) 1.34(0.84-2.14) 0.216
Endocrine therapy (no/yes) 0.48(0.26-0.88) 0.018 0.114
Chemotherapy (no/yes) 1.56(1.05-2.33) 0.029 0.611
LBVIH&E (absent/present) 2.39(1.61-3.54) <0.001 0.196
LVID2–40 (absent/present) 3.31(2.19-4.97) <0.001 1.69(1.08-2.67) 0.023
BVIFVIII (absent/present) 5.12(3.38-7.78) <0.001 3.35(2.21-5.63) <0.001
Node-negative patients (n = 212)
age (≤50/ >50 years) 0.69(0.36-1.36) 0.290
Size (≤20/ 21-50/ >50 mm) 2.33(2.32-3.31) 0.007 1.93(1.04-3.59) 0.038
Grade (I / II / III) 1.64(1.64-2.74) 0.061 0.184
ER (no/yes) 0.75(0.38-1.45) 0.388
PR (no/yes) 0.91(0.47-1.78) 0.780
HER2 status (no/yes) 2.11(1.03-4.31) 0.040 0.368
Endocrine therapy (no/yes) 0.91(0.41-2.02) 0.822
Chemotherapy (no/yes) 0.83(0.39-1.72) 0.612
LBVIH&E (absent/present) 2.43(1.21-4.89) 0.010 0.649
LVID2–40 (absent/present) 3.24(1.67-6.29) 0.001 2.29(1.15-4.58) 0.004
BVIFVIII (absent/present) 6.03(2.87-13.77) <0.001 4.43(2.07-9.51) 0.001
Triple-negative patients (n = 120)
age (<50/ >50 years) 1.09(0.57-2.01) 0.784
Size (≤20/ 21-50/ >50 mm) 3.43(2.01-5.85) <0.001 2.94(1.65-5.24) <0.001
Grade (I / II / III) 0.79(0.39-1.58) 0.503
Involved lymph node (−ve/+ve) 4.08(2.01-8.27) <0.001 2.36(1.11-5.03) 0.026
Endocrine therapy (no/yes) 0.89(0.27-2.89) 0.842
Chemotherapy (no/yes) 0.93(0.48-1.78) 0.824
LBVIH&E (absent/present) 2.31(1.21-4.42) 0.011 0.294
LVID2–40 (absent/present) 3.57(1.82-7.04) <0.001 2.61(1.36-5.04) 0.014
BVIFVIII (absent/present) 4.68(3.09-10.31) <0.001 3.63(1.38-6.56) 0.001
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tinuous and the myoepithelial cells of larger ducts are lar-
ger than the endothelial cells of lymph vessels [39].
Finally, the distribution of the stain for the myoepithelial
cells is recognised to be patchy and the intensity less than
that of the adjacent lymphatic endothelium [40]. There-
fore, increase in sensitivity of detection of lymph vessel in-
vasion may be reasonably attributed to the demarcation of
lymphatic endothelium that stains positively for D2-40around the tumour emboli and although, D2-40 may also
bind to myoepithelium of breast ducts, it is not difficult to
distinguish between myoepithelial reactivity and endothe-
lial staining of the vessels.
Factor VIII has been previously reported as a blood
vessel endothelial marker in breast cancer and is con-
sistently found in normal endothelial cells in blood
vessels. While it occasionally stains endothelial cells in
lymphatics, staining of lymphatic endothelium is usually
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gested that the vascular marker CD31 may be superior to
factor VIII for blood vessels staining [42,43]. However,
another study reported that the higher sensitivity of
CD31 of vascular endothelium did not yield results
more discriminating for predicting survival outcome
than results produced with factor VIII [44].
In the present study, although the value of lymphovascu-
lar invasion detected using IHC was significantly correlated
with the value of lymphovascular invasion detected using
H&E (P < 0.001), 80 (22%) patients that were negative for
lymphovascular invasion on H&E showed positive LVID2–40
and/or BVIFVIII, indicating that the frequency of detection
of lymphovascular invasion increased using IHC. These
lesions were difficult to identify on the H&E sections
due to invasion into small lymphatic or blood vessels or
due to vessels that had been obscured by tumour cells.
Thirty four patients had tumours that were LBVIH&E
positive, were negative for both LVID2–40 and BVIFVIII.
A recognised explanation for such a discrepancy is that
stromal retraction artifacts, caused by tissue handling and
fixation, on H&E sections cause false positives [7,21-23].
In addition, the H&E approach has considerable interob-
server variability and lower overall detection rate in most
previous studies [24]. The significance of this is that
although AJCC guidelines mandate the reporting of lymph-
atic and blood vessel invasion, they lack a routine standard-
ized pathological methodology to reliably report them.
The results of the present and previous studies [24] point
to a substantial improvement in the consistency of report-
ing and an increase in the rate of detection of LBVI, LVI
and BVI in patients with breast cancer cases using an IHC
approach. Such an improvement has been documented
with lymphatic (eg, podoplanin/D2-40) and blood vessel
(eg, CD34 and CD31) endothelial markers. Moreover,
these markers not only discriminate retraction artifacts
from LVI and BVI but also distinguish between lymph
vessels and blood vessels, allowing specifically study of
LVI and BVI [7,16,21,36,39].
A limitation of the present study was that intra- and
peritumoral LBVI foci were not separately analysed owing
to small number of cases with intratumoural LBVIH&E
(5%) compared to the (95%) of peritumoural LBVIH&E.
This precluded meaningful analysis of each component
but was unlikely to materially influence the concordance
between the detection of LBVI-H&E and LBVI-IHC.
Although, several previous studies have reported the
prognostic significance of LBVI using H&E staining
these studies have not discriminated between the types
of vessel invasion whether lymphatic or blood vessel and
have inconsistently used the terms vascular or lymphovas-
cular invasion. For example, the American Joint Committee
on Cancer (AJCC) staging guidelines (2005) has used the
term lymphovascular invasion to indicate both lymphaticand vascular involvement [20]. This clearly may be confus-
ing as these terms may indicate involvement of lymphatic
or lymphatic and blood vessels. This is largely a pragmatic
approach to the limitations of the routine use of H&E slides
to assess lymphovascular invasion. Another limitation was
that the well established factors such as grade and ER status
were not independently associated with cancer specific
survival in all patients and in those with node-negative or
triple-negative disease. This may suggest that the sample
size was rather small for such multivariate analysis. Never-
theless, the results are of interest and make a case for fur-
ther studies of routine clinical assessment of lymphatic and
blood vessel invasion by IHC to ascertain LVI and BVI.
Conclusions
In summary, the results of the present study show that
IHC for D2-40 and Factor VIII define lymphatic and blood
vessel invasion with greater sensitivity and specificity than
H&E, improving detection of LVI and BVI in early invasive
breast cancer. Moreover, the prognostic significance of the
LVID2–40 and BVIFVIII was superior to that of LBVIH&E and
this was consistent throughout analysis of sub-cohorts.
Therefore, these results make the case for their assessment
in routine clinic-pathological practice.
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